https://www.selleckchem.com/pr....oducts/bms-986020.ht
524, p=0.003). In contrast, the incidence of 30-day AIS development showed no significant increase (adjusted HR=1.301, p=0.426). AF patients who underwent ECV had a higher incidence of 7-day AIS development but not 30-day AIS development. Considering the timing of AIS development after ECV in AF patients, the optimal duration of antithrombotic therapy after ECV deserves further investigation. AF patients who underwent ECV had a higher incidence of 7-day AIS development but not 30-day AIS development. Considering the timing of AIS dev
Me gusta
Comentario
Compartir
